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The chaperonin activity of sequence-related chapero-
nin 10 proteins requires their aggregation into hep-
tameric structures. We describe size-exclusion chroma-
tography and ultracentrifugation studies that reveal
that while Escherichia coli chaperonin 10 exists as a
heptamer, the Mycobacterium tuberculosis chaperonin
10 is tetrameric in dilute solutions and in whole M. tu-
berculosis lysate. At high protein concentration and in
the presence of saturating amounts of divalent ions, the
protein is heptameric. Human chaperonin 10 is predom-
inantly heptameric, although smaller oligomers were
detected. These differences in structural assembly be-
tween species may explain differences in biological ac-
tivity such as antigenicity.
Using C-terminal and N-terminal fragments, sequence
1–25 was identified as indispensable for aggregation. CD
spectroscopy studies revealed that (i) a minimum at 202–
204 nm correlates with aggregation and characterizes
not only the spectrum of the mycobacterial protein, but
also those of E. coli and human chaperonin 10 proteins;
(ii) the interactions between subunits are of the hydro-
phobic type; and (iii) the anti-parallel b-pleated sheet is
the main secondary structure element of subunits in
both tetrameric and heptameric proteins.
The sequence-related chaperonin 10 (cpn10,1 hsp10, or 10-
kDa antigen) class of proteins assists the noncovalent assembly
of other protein-containing structures in vivo (1). This biologi-
cal activity requires aggregation of cpn10 into a heptameric
structure (2). In addition to this activity, several cpn10 proteins
such as the Mycobacterium tuberculosis and Mycobacterium
leprae molecules are among the most potent stimulators of the
immune system known (3–8). For example, in a leprosy pa-
tient, one in three T lymphocytes that respond toM. lepraemay
react to M. leprae cpn10 (4). Similarly, M. tuberculosis cpn10
induces T cell proliferation in healthy tuberculin reactors to an
extent that is greater than that elicited by any other mycobac-
terial protein (5). Intriguingly, there is a dramatic difference in
antigenicity between cpn10 proteins from different species:
human cpn10 and Escherichia coli cpn10, for instance, are very
poor immunogens (9).
In addition to antigenicity, chaperonins, at low concentra-
tions, have other biological properties. For example, several
micrograms or less of mycobacterial chaperonins/milliliter will
immunize animals, stimulate T lymphocyte proliferation in
vitro, and induce cytokine secretion from a human monocyte
line and from human monocytes (3–8, 10, 11). They also induce
apoptosis of human p19 cells.2 Furthermore, there is evidence
to suggest that human cpn10 may be involved in control over
cell growth and development (9). These data indicate that
cpn10 proteins have several distinct biological activities,
namely as molecular chaperones and non-chaperone activities.
This study concerns the aggregation behavior of the M. tu-
berculosis cpn10 protein under a variety of different experi-
mental conditions, in particular, low concentrations of cpn10 at
which non-chaperone activities occur. Aggregation of both the
full-length protein and truncated cpn10 peptides was exam-
ined. Furthermore, the secondary structure of the molecule was
analyzed by CD spectroscopy. Most of the work was carried out
using chemically synthesized full-length protein including the
N-terminal and C-terminal fragments. Recombinant material
was used for comparison.
Preliminary accounts on both the synthesis of the protein
and its structure have been reported previously (13, 14). Here,
we demonstrate thatM. tuberculosis cpn10 exists, surprisingly,
as a tetrameric aggregate with b-type structure in dilute solu-
tions and in whole M. tuberculosis lysate. In the presence of a
large molar excess of divalent ions, the protein has the expected
heptameric structure and, together with cpn60, is functional in
a refolding assay. In contrast, we show that E. coli cpn10 is
heptameric under all conditions tested, while human cpn10 is
predominately found as a heptamer, although dissociation into
smaller oligomers takes place under certain solution condi-
tions. These differences in structural assembly between species
may help to explain differences in biological activity such as
antigenicity.
MATERIALS AND METHODS
Chemical Synthesis of M. tuberculosis cpn10 and Fragments—The
synthesis and purification of theM. tuberculosis protein and C-terminal
and N-terminal fragments were performed by the solid-phase stepwise
approach using t-butoxycarbonyl chemistry and according to a strategy
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that uses chromatographic probes for the selective purification of syn-
thetic proteins (15–17).3 The details of this strategy applied to M.
tuberculosis cpn10 and its fragments will be described elsewhere.4 The
material was, however, homogeneous by reversed-phase HPLC and had
the correctMr (peptide 1–99, 10,674; peptide 1–58, 6213; peptide 59–99,
4477; peptide 51–99, 5480; and peptide 26–99, 8007), sequence, and
amino acid composition.
M. tuberculosis Lysate—Nonviable desiccated M. tuberculosis H37
RA (Difco) was used as source of naturally expressed M. tuberculosis
cpn10. 200 mg of desiccated material was resuspended in 50 mM Tris,
150 mM KCl, 5 mM MgSO4, 2.5 mM phenylmethylsulfonyl fluoride, 1 mM
aprotinin, pH 7.4, and 50 mg of glass beads (150–210 mm; Sigma) were
added. Protein extraction was performed by sonication of the suspen-
sion on ice (3 3 10 min, with a 1-min interval in between). After
sonication, the suspension was centrifuged for 10 min at 13,000 rpm
and 4 °C, and the supernatant was analyzed for protein content using
the bicinchoninic acid protein assay (Pierce). An aliquot of the extract
(corresponding to 70 mg of protein) was separated on a Superdex 75 SEC
column using 50 mM Tris, 150 mM KCl, 1 mM MgSO4 as a buffer, and
fractions of 0.5 ml each were collected. Fractions of 100 ml each were
coated on a 96-well microtiter plate (Nunc ImmunoPlate MaxiSorp),
and detection of M. tuberculosis cpn10 was performed using a mono-
clonal antibody (SA12) specific for mycobacterial cpn10 (27) following
standard enzyme-linked immunosorbent assay techniques.
Recombinant M. tuberculosis, E. coli, and Human cpn10 Proteins—E.
coli cpn10 was purchased from Boehringer Mannheim and was used
without further purification. Human cpn10 was expressed in E. coli and
purified by reversed-phase HPLC as previously reported (19).M. tuber-
culosis was expressed either in baculovirus and purified by isoelectro-
focusing in solution (20) or in E. coli. The details of expression in E. coli
and purification will be described elsewhere. Briefly, for expression, the
T7 expression system was used. Polymerase chain reaction amplifica-
tion was performed using a pUC18 plasmid that contains the M. tuber-
culosis groESL-like operon as template. The resulting plasmid coding
forM. tuberculosis cpn10 was transformed into BL21(DE3). Expression
was carried out at 37 °C in M9ZB medium. Cells were harvested by
centrifugation, resuspended in lysis buffer (50 mM Tris-HCl, 2 mM
EDTA, pH 8.0), and centrifuged again. The pH of the supernatant was
adjusted to 2.2 with trifluoroacetic acid, the suspension was centri-
fuged, and the resulting supernatant was applied directly to a semi-
preparative reversed-phase HPLC column (Vydac C18, 9 3 25 mm). The
protein eluted at a concentration of acetonitrile N of ;40%. Fractions
containing homogeneous material were pooled and lyophilized. The
purity of the protein thus obtained was .95% as judged by both ana-
lytical HPLC and capillary electrophoresis. The entire expression and
purification protocol yielded ;100 mg of pure (.95%) protein/liter of
expression medium.
Size-exclusion Chromatography—Gel filtration experiments were
conducted on a Superdex 75 column connected to a fast protein liquid
chromatography instrument (Pharmacia) and a Jasco 875-UV detector.
The column was calibrated using a mixture of globular standard pro-
teins (Pharmacia Biotech low molecular weight gel filtration calibration
kit) whose retention times were not affected by the different buffers
used. Samples were eluted at 0.5 ml/min, and column effluent was
monitored at both 280 and 214 nm.
Ultracentrifugation—A Beckman Optima XL-A analytical ultracen-
trifuge equipped with modern scanning absorption optics was used in
all investigations. Sedimentation equilibrium experiments were per-
formed at 20,000 and 30,000 rpm, scanning at 220, 230, and 280 nm and
using the buffer as reference solvent at a temperature of 20 °C. For the
experiments, six-channel 12-mm Kel-F (Beckman Instruments)
“Yphantis cells” (21, 22) were used. The concentrations employed were
0.05, 0.2, and 1 mg/ml depending on the sample. The sedimentation
equilibrium data were evaluated using the MSTARA program, which is
described elsewhere (23). The solvent densities needed for the evalua-
tion were determined at 20 °C using an Anton Paar Model DMA O2C
precision density meter calibrated with CsCl solutions (24). For each
density value, 10 consistent readings were obtained to minimize the
experimental error. The partial specific volumes of the chaperones were
calculated from their amino acid composition using the consensus for-
mula given by Perkins (25).
CD Spectroscopy—CD measurements were performed on a Jasco
J-600 spectropolarimeter calibrated with d-10-camphorsulfonic acid.
Spectra, unless otherwise specified, were recorded in 0.1 M phosphate
buffer at 22 °C in a cuvette with a 0.1-cm path length. Peptide and
protein concentrations were kept at 0.1 mg/ml in all experiments.
Spectra were the average of eight scans at 50 nm/min, each with a
bandwidth set at 2 nm, and were base line-corrected by subtracting the
corresponding blank. Although spectra were recorded in the 190–240
nm range, data below ;195 nm were not always reliable due to strong
interferences of the solvent (0.1 M phosphate) at these wavelengths. The
observed ellipticity was converted to mean residue weight ellipticity
([Q]/(degreeszcm2zdmol21)). Smoothing of the curves, using a mild func-
tion that increased the signal-to-noise ratio without altering the shape
of spectra, was applied using the Jasco J-700 program. Superimposition
of smoothed spectra with the raw curve was performed each time to
check for artifacts.
pH titration experiments were performed by preparing a stock solu-
tion of peptide (2 mg/ml in either distilled water or slightly acidified
water) and mixing aliquots of this solution with sufficient phosphate
solution buffered at the pH of choice so as to yield a final solution
containing 0.1 mg/ml peptide in 0.1 M phosphate. The exact pH was
then monitored with a pH-meter equipped with a microelectrode. Prior
to use, the final solution was equilibrated for 1 h at 22 °C in the CD
chamber. During temperature studies, the cuvette containing the pep-
tide solution and the CD chamber were equilibrated for 1 h prior to
collection of data.
RESULTS
Fig. 1 shows the sequences of the three proteins considered
in this work. Two of the M. tuberculosis cpn10 fragments (i.e.
peptides 1–58 and 59–99) were selected because they include
or exclude, respectively, a sequence (amino acids 46–59) pre-
dicted to be a loop region (Fig. 1). This loop contains the M.
tuberculosis cpn10 monoclonal antibody (SA12)-binding site (5,
26, 27). SA12 is, within the cpn10 family, specific for the my-
cobacterial molecule. There were no special reasons for the
3 H. L. Ball and P. Mascagni, submitted for publication.
4 G. Fossati, G. Legname, P. Lucietto, H. L. Ball, P. Giuliani, A. R.
Coates, and P. Mascagni, manuscript in preparation.
FIG. 1. Alignment and secondary structure prediction of the M. tuberculosis (mt), E. coli (ec), and human (hu) cpn10 proteins
discussed under “Results.” Numbering of residues refers to the M. tuberculosis protein. Footnote a, shown is the cpn10 motif described in the
SWISS-PROT data base (release 30.0, October 1994). h, hydrophobic residues; q, mostly charged residues (Lys, Arg, Glu) or Gln. Footnote b, the
secondary structure composition of cpn10 proteins was predicted by first aligning 27 sequences of cpn10 proteins and then considering the
secondary structure of each section (separated by gaps) using two different algorithms: Chou-Fasman (12) and GORII (18). II Str.Pred., secondary
structure prediction; h, a-helix; b, b-strand; t, turn; l, loop. Boldface residues denote identity.
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choice of the other two fragments other than the fact that
peptide 51–99 cuts almost in the middle the loop antibody-
binding region. This could provide information about which
residues are necessary for antibody recognition. Peptide 26–99
begins with a conserved Gly, which follows a long sequence
predicted to be another loop region (Fig. 1).
Chemical Synthesis
Preliminary accounts on the synthesis of M. tuberculosis
cpn10 have been described previously (13, 14), while a complete
account of the details will be reported elsewhere.4 Here it
should be noted that we have developed highly effective proto-
cols for stepwise solid-phase synthesis of proteins and their
purification. These protocols require (i) removal of deletion
sequences by capping unreacted amino groups after each cou-
pling step; (ii) addition of a chromatographic probe with en-
hanced lipophilic character to the last residue of the sequence;
(iii) separation by reversed-phase HPLC of the probe-protein
adduct from truncated sequences; and finally, (iv) removal of
the probe by mild basic treatments (15–17).3 The proteins thus
recovered have a degree of purity generally .85%, as deter-
mined by a combination of mass spectrometry, HPLC, and
capillary electrophoresis3 and are further purified by either
ion-exchange chromatography or isoelectrofocusing techniques.
The M. tuberculosis protein was synthesized and purified
according to these protocols. The final purified product had the
correct mass, amino acid composition, and sequence.4 Further-
more, samples of recombinant material that became available
during the final stages of this study were found to have the
same physicochemical characteristics as synthetic M. tubercu-
losis protein.
Aggregation Studies
The synthetic protein and fragments were first analyzed by
SEC for their ability to aggregate. In PBS, pH 7.4, the protein
had an apparent molecular mass of ;40 kDa, which corre-
sponded to an aggregation state of 4 (Fig. 2 and Table I). This
was quite surprising since all cpn10 proteins reported to date
have been described as heptamers. Indeed, samples of recom-
binant human and E. coli cpn10 proteins were found to be
heptameric by the same technique (Table I). The synthetic
origin of the protein was not responsible for this unexpected
result since a sample of purified recombinant material had an
identical SEC profile (Fig. 3). Furthermore, enzyme-linked im-
munosorbent assays using the M. tuberculosis cpn10-specific
monoclonal antibody SA12 and SEC fractions of whole Myco-
bacterium lysate identified only one protein whose molecular
mass corresponded to that of tetrameric cpn10 (Fig. 3).
The two larger fragments, i.e. peptides 26–99 and 51–99,
also had retention times that, in a calibration curve, corre-
sponded to an aggregation state of 4. A similar conclusion was
reached when peptide 1–58 was tested, while peptide 59–99
eluted as either a trimer or dimer. The apparent molecular
mass of the polypeptides did not change in the pH range 5–8.5,
at which a calibration curve was still reliable using standard
proteins (data not shown).
Given the unexpected nature of the oligomeric state of the
protein, a second independent measurement of the aggregation
properties of the cpn10 molecule was carried out by analytical
ultracentrifugation (AUC). This confirmed that in PBS, pH 7.4,
M. tuberculosis cpn10 was a tetramer (Table I). However, the
fragments gave the following results. At concentrations vary-
ing between 0.05 and 1 mg/ml, peptide 1–58 was always a
dimer, while all other C-terminal fragments were, in the same
concentration range, monomeric (Table I). Given that, in some
cases, the results from the two techniques (SEC and AUC)
differed, and due to the superior reliability of AUC in the
determination of the molecular mass, the values obtained from
ultracentrifugation were taken as representative of the aggre-
gation state of the polypeptides.
To explore the possibility that the M. tuberculosis cpn10
protein could adopt a heptameric form, a binding test was
carried out with recombinant E. coli cpn60 (GroEL). Thus, it is
well established that in order to exert its activity, the co-
chaperone cpn10 protein must bind to cpn60 in the presence of
Mg21/ATP (see, for example, Ref. 28). Furthermore, electron
microscopy studies have shown that both proteins share a
7-fold axis of symmetry when in the complexed form (see, for
example, Ref. 29). Indeed, M. tuberculosis cpn10 bound to
GroEL, and the complex thus obtained was a functional one in
a refolding assay.4 These data suggest either that GroEL acts
as a chaperone for the cpn10 protein by changing its aggrega-
tion state from 4 to 7 or that the smaller protein binds to GroEL
in a tetrameric state. Alternatively, the transition between the
two different aggregation states is due to the presence in the
buffer of either ATP or Mg21 ions or both. This hypothesis was
verified by additional SEC experiments in the presence of
Mg21/ATP. Magnesium ions alone were sufficient to change the
aggregation state of cpn10 to 7 (Fig. 2 and Table I). Ultracen-
trifugation studies conducted under the same conditions con-
firmed this conclusion (Table I). A similar, although not quite
so dramatic effect has been recently described for the cpn60
protein. Cross-linking of the native GroEL tetradecamer is
accelerated by saturating amounts (10 mM) of Mg21 ions (30).
Mg21 could be substituted with Mn21 and Ca21 ions in
inducing the change to heptamers, while monovalent ions, such
as K1, were ineffective (Table I). In the case of Zn21 ions, a
heptameric species and small amounts of larger aggregates
were obtained (Table I). As to the shorter fragments, their
aggregation states were not influenced by the addition of diva-
lent ions, their retention times being the same in the presence
or absence of Mg21 (data not shown).
To evaluate whether parameters other than the divalent
cations could influence the aggregation of the protein, addi-
tional SEC and AUC studies were carried out. Protein concen-
FIG. 2. Size-exclusion chromatography of M. tuberculosis
cpn10 (0.2 mg/ml) in PBS, pH 7.4, and in PBS plus 7 mMMg21. The
addition of the latter changed the aggregation state of the protein from
4 to 7. BSA, bovine serum albumin; OVA, ovalbumin.
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tration and type of buffer were examined. Also, solution pH was
studied (by ultracentrifugation only) because the CD results
(see below) indicated that both the protein and its C-terminal
fragments undergo a conformational change at acidic pH
values.
When the protein concentration was kept between 0.1 and
0.2 mg/ml, an aggregation state of 4 was found irrespective of
the buffer used (i.e. 0.1 mM Tris with or without 10 mM KCl and
PBS without Mg21/Ca21) (Table I). The addition of Mg21 con-
verted the protein to a heptamer in all of these solvents. When
the concentration of the protein was increased to 1 mg/ml and
the solvent was 0.1 M phosphate, the heptamer was the most
abundant species in solution (;95%) even in the absence of
Mg21. Interestingly, lowering the phosphate concentration to
TABLE I
Summary of salient analytical ultracentrifugation and size-exclusion chromatography results on cpn10 proteins and
M. tuberculosis cpn10 fragments
Peptide Technique Solventa Concb
Mr
c and aggregation state
pH 7.4 2.0 ¶ pH ¶ 3.4
E. coli cpn10 AUC C C2 70,000 6 5000 (n 5 7)
SEC D/D1Mg21/K1 C2 70,000 (n 5 7)
SEC A/A1Mg21 C2 70,000 (n 5 7)
Human cpn10 SEC A/A1Mg21 C2 70,000 (n 5 7)
SEC D1K1 C2 Mainly 40,000 (n 5 4)
M. tuberculosis cpn10 AUC C1Mg21 C3 75,000 6 5000 (n 5 7)
AUC A C2 47,000 6 5000 (n 5 4)
AUC A C1 40,000 6 10,000 (n 5 4)
AUC B C2 45,000 6 5000 (n 5 4)
d
SEC D/A C2 40,000 (n 5 4)
SEC D1Mg21/Ca21/Mn21 C2 70,000 (n 5 7)
SEC D1Zn21 C2 70,000 (90%; n 5 7)
.100,000 (10%; n 5
NM)
SEC A1Mg21 C2 70,000 (n 5 7)
SEC C C3 70,000 (95%; n 5 7)
40,000 (5%; n 5 4)
Peptide 59–99 AUC A C2 5000 6 1000 (n 5 1)
AUC A C1 5000 6 1000 (n 5 1)
AUC B C2 6000 6 2000 (n 5 1)
e
Peptide 51–99 AUC C C3 3500 6 1000 (n 5 1)
AUC C C2 3500 6 1000 (n 5 1) 10,000 6 500 (n 5 2)
f
Peptide 26–99 AUC C C3 5000
g (n 5 1)
AUC C C2 7000 6 3000 (n 5 1) 17,000 6 1000 (n 5 2)
f
Peptide 1–58 AUC C C3 10,000 6 1000 (n 5 2)
AUC A C2 10,000 6 2000 (n 5 2)
AUC A C1 9500 6 2000 (n 5 2)
a A 5 PBS; B 5 0.01 M phosphate; C 5 0.1 M phosphate; D 5 0.1 M Tris.
b C1 5 0.05 mg/ml; C2 5 0.2 mg/ml; C3 5 1 mg/ml. Ions such as Mg
21, Ca21, Mn21, Zn21, and K1 were added to the buffer of choice to a final
concentration of 7 mM.
c In the case of SEC the Mr was obtained from calibration curves and is approximated to the nearest thousand. n is the number of subunits
contained in the aggregate.
d pH 2.0.
e pH 3.0.
f pH 3.4.
g Noisy data; it was not possible to calculate the error.
FIG. 3. Enzyme-linked immunosor-
bent assays on size-exclusion chro-
matography fractions of recombi-
nantM. tuberculosis cpn10 (l) andM.
tuberculosis lysate (M). Fractions (0.5
ml) were collected every minute after 13
min from injection. 100 ml of each fraction
were coated on a 96-well microtiter plate,
and the presence ofM. tuberculosis cpn10
was revealed with the M. tuberculosis
cpn10 monoclonal antibody SA12 using
standard enzyme-linked immunosorbent
assay techniques. BSA, bovine serum al-
bumin; OVA, ovalbumin.
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that of PBS (i.e. ;10 mM) while maintaining the protein con-
centration at 1 mg/ml gave aggregation species that ranged
from that of a heptamer to either a dimer or trimer (Fig. 4A and
Table I). Finally, at acidic pH and in 10 mM phosphate buffer,
the protein was still a tetramer (Table I).
Similar studies conducted on recombinant E. coli cpn10 (also
known as GroES) showed that the protein existed in solution
only as a heptamer (Table I). Human cpn10 had instead a
behavior intermediate between that of GroES and that of M.
tuberculosis cpn10 since it was heptameric in all cases tested,
except in a 0.1 M Tris solution, pH 7.4, where it was a mixture
of various aggregation states (Fig. 4B), and in the same solu-
tion plus 10 mM KCl, where it was mainly tetrameric (Table I).
Finally, peptides 26–99 and 51–99, which were not influenced
by all the parameters discussed above (data not shown), be-
came dimers at pH 3.4, while peptide 59–99 was still mono-
meric at a similar pH (Table I).
CD Spectroscopy
The fragments and the M. tuberculosis cpn10 protein (0.1
mg/ml) were initially studied in phosphate buffer (0.1 M) at
neutral pH (Fig. 5A). With the exception of peptide 59–99,
which had minima at about 215 and 202 nm, the other mole-
cules had either an intense band at 198 nm and a shoulder at
;220 nm (peptides 51–99 and 26–99) or a minimum at 203 nm
and shoulders at about 198 and 217 nm (full-length protein).
Furthermore, the intensities of the spectra decreased on going
from peptide 51–99 to protein. Peptide 1–58, in addition to the
intense band at 198 nm, had a shoulder between 225 and 230
nm (Fig. 5A). A more detailed study on the CD structure of
these peptides was then carried out, beginning with the short-
est sequence.
Peptide 59–99—The CD spectrum of this peptide was the
only one of those shown in Fig. 5A with an apparently more
defined secondary structure composition. CD spectra with min-
ima between 215 and 220 nm have been attributed to proteins
with a high content of anti-parallel b-sheet and a nonsecondary
structure contribution from aromatic residues (this peptide
contains four tyrosines) (31).
pH titration experiments led to a decrease of the contribution
at 202 nm and an increase in the minimum at 215 nm (Fig. 5B).
At pH 3.0, where the peptide had a stable structure (32) and
was monomeric, there was only the band at 215 nm.
Peptide 51–99—The addition of only eight residues to pep-
tide 59–99 dramatically affected the CD spectrum of the re-
sulting 51–99 molecule. Thus, although a b-sheet contribution
could still be deduced from the shoulder at 220 nm, the main
CD band was at 198 nm (Fig. 5, A and C). Changing the
solution pH led to a blue shift of the former to 217 nm and an
increase in its intensity, which became maximal at pH 3.5. At
this pH, a minimum at 204 nm replaced that at 198 nm (Fig.
5C). Notice that the presence of the latter could not be excluded
since the 204 nm band was very broad. Under these conditions
of solvent composition and pH, the peptide was a dimer (see
above and Table I).
Peptide 26–99—A trend similar to that found for peptide
51–99 applied to peptide 26–99, which was monomeric and
dimeric at neutral and acidic pH, respectively. Thus, the broad
and intense signal centered at 198 nm in the spectrum at pH
7.4 moved, at pH 3.4, to ;203 nm, while the shoulder at 220 nm
became more intense and shifted to 215 nm (Fig. 5D). An
isosbestic point at 209.5 nm, essentially in the same position as
that of peptide 59–99, characterized the pH titration
experiment.
Peptide 1–58—Unlike the other fragments, the region of the
protein corresponding to its N-terminal half was dimeric at
neutral pH and at a wide range of peptide concentrations (i.e.
0.05–1 mg/ml) (Table I). The spectrum at pH 7.4 had an intense
band at 198 nm and a shoulder between 225 and 230 nm (Fig.
5A) and did not change upon varying the solution pH (data not
shown).
Peptide 1–99—As discussed above, the M. tuberculosis pro-
tein adopts, in the absence of divalent cations, a tetrameric
structure unseen in the case of other members of this class of
proteins. CD studies were therefore conducted not only as a
function of the solution pH, but also in the presence of Mg21
and as a function of temperature and solvent composition.
The spectrum of the M. tuberculosis protein (Fig. 5A) was
qualitatively similar to those of E. coli cpn10, synthetic rat
cpn10 (14), and recombinant human cpn10. In particular, the
E. coli protein had a minimum at 202 nm and a shoulder at 197
nm, while human cpn10 (and rat cpn10; the two proteins differ
by one residue) had minima at 203 and 197 nm (Fig. 6). Thus,
the band at 202–203 nm and the shoulder at 197–198 nm are
characteristic of this class of proteins and independent of their
origin or aggregation state.
The intensity of the 204 nm band was, however, larger in the
case of mammalian and E. coli proteins. The aggregation state
was only partly responsible for these changes since the spec-
trum of the M. tuberculosis protein in its heptameric state (i.e.
in the presence of Mg21; see below) was still less intense than
those of the other two chaperonins. Possible explanations for
this difference could be either the presence in solution of small
FIG. 4. Size-exclusion chromatography of M. tuberculosis
cpn10 (1 mg/ml) in PBS, pH 7.4 (top trace), and human cpn10 (0.2
mg/ml) in 0.1 M Tris buffer, pH 7.4 (bottom trace), illustrating the
presence of different oligomeric structures.
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concentrations of tetrameric M. tuberculosis cpn10 or a differ-
ence balance, in the three proteins, of the residues/regions
contributing to the 204 nm band and the less intense 198 nm
band.
Lowering the pH of M. tuberculosis cpn10-containing solu-
tions induced a shift to 204 nm of the broad signal at 203 nm
similar to that seen for the C-terminal fragments, while the
shoulder at 217 nm became more pronounced (Fig. 7A). An
isosbestic point at 210.5 nm, together with invariance of the
spectral features between pH 4.5 and 2 (spectra in this pH
range were essentially identical; data not shown), indicated the
existence of an equilibrium between at least two species, one
(or more) at pH 7.4 and a second conformation stable in the pH
4.5 to 2 interval.
Qualitatively, the addition of Mg21, which aggregation stud-
ies had shown to induce a transition from tetramers to hep-
tamers, led to the same changes (i.e. shift of the 203 nm band
to 204 nm and increase in the intensity of the 217 nm shoulder)
observed during pH titration (Fig. 7B). In particular, virtually
no changes were observed when 1 or ,1 eq (CMg21 # ;0.01 mM)
FIG. 5. CD spectra of M. tuberculosis cpn10 and fragments. A, M. tuberculosis cpn10 and C-terminal fragments (0.1 mg/ml) in 0.1 M
phosphate buffer, pH 7.4. The spectrum of peptide 1–58 is shown in the inset. The spectra of the C-terminal fragments had different intensities
(see “Results,” the other panels of this figure, and Fig. 7). Therefore, to enable their visual comparison, the spectra of peptides 59–99 and 26–99
and the full-length protein were multiplied by factors of 6, 12, and 300, respectively. B, CD curves of peptide 59–99 at different pH values. All
fragments and the full-length protein were scarcely soluble in the approximate pH range 4–5.5. Spectra at these pH values were therefore not
obtained. C, as in B, but for peptide 51–99. D, as in B and C, but for peptide 26–99. WL, wavelength.
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of magnesium ions/protein subunit was added, while a contin-
uous change in the shape of the spectrum was obtained upon
adding 5 eq of Mg21 (0.05 mM) and up to a total magnesium
concentration of ;5 mM. These results suggested that there
was no stoichiometric binding of the ion to the cpn10 protein.
Modulation of the intensities of the minima at ;200 nm also
occurred during temperature studies. Thus, at 0 °C, the spec-
trum had two almost equally intense bands, at 199 and 203 nm,
respectively, while raising the temperature to 30 °C led to a
sharpening of the latter, which moved to 204 nm. At this
temperature, the 198 nm contribution was reduced consider-
ably (Fig. 7C).
Finally, the addition of MeOH to aqueous solutions of M.
tuberculosis cpn10 led to a CD spectrum resembling that of an
all-b-structure (Fig. 7D) (31). This suggested that the ability to
form anti-parallel b-strands shown by the C-terminal frag-
ments was maintained in the full-length protein.
DISCUSSION
The work that we describe here provides, for the first time,
CD data on the secondary structure of M. tuberculosis cpn10,
leads to a hypothesis for the tertiary structure, and demon-
strates, surprisingly, that the main quaternary unit is a tet-
ramer. The following is a detailed discussion of the main
findings.
Aggregation—cpn10 proteins are known to assemble into
heptameric structures and, in the presence of Mg21/ATP, form
a complex with cpn60 tetradecamers that functions as a mo-
lecular chaperone. Electron microscopy studies have shown
that both cpn10 and cpn60 share a 7-fold axis of symmetry in
the complexed form (see, for example, Ref. 29). Prior to the
present work, these structures were reported to be quite stable
(33). The results of SEC and AUC that we reported here con-
firm that E. coli and human cpn10 heptamers are stable under
a wide variety of conditions, but, surprisingly, M. tuberculosis
cpn10 is predominantly a tetramer under most of the condi-
tions tested. Heptameric species were also obtained and shown
to prevail in the presence of a large molar excess of divalent
ions (e.g.Mg21, phosphate, etc.). The role of the latter does not
seem to involve secondary structure changes deriving from an
increase in the solution ionic strength since replacing magne-
sium with potassium did not lead to heptamerization. A possi-
ble explanation for these observations is that divalent ions
bring the surfaces of neighboring subunits into closer contact
with one another.
The heptameric structure of M. tuberculosis cpn10 acts as a
molecular chaperone by binding to E. coli cpn60 and generating
a complex functional in a refolding assay. This shows that both
M. tuberculosis cpn10 and E. coli cpn10 associate in the same
way, i.e. as heptamers with the cpn60 tetradecamer.
What is the significance of tetramericM. tuberculosis cpn10?
The first clue comes from the our observation that M. tubercu-
losis cpn10 is tetrameric in low protein and low divalent ionic
solutions. This suggests that, in nature, where a wide variety of
conditions are present, the tetrameric form may predominate.
Indeed, this appears to be the case sinceM. tuberculosis lysate
has only one species that binds to anti-cpn10 monoclonal anti-
body and has the molecular mass of a tetramer. (It is important
to note that the monoclonal antibody used in this experiment
binds to both tetrameric and heptameric forms of M. tubercu-
losis chaperonin,5 ruling out the existence of heptameric spe-
cies in mycobacterial lysate.)
Is M. tuberculosis cpn10 biologically different from E. coli or
mammalian cpn10? The most obvious difference is immunoge-
nicity. For example, M. tuberculosis cpn10 is highly antigenic
(3–7) while E. coli and mammalian cpn10 proteins are not (9).
Furthermore, recent data suggest that M. tuberculosis cpn10
can stimulate monocytes (10), macrophages (11), and synovial
fibroblast-like cells.6 In contrast, human and E. coli cpn10
proteins are poor immunogens (9). It is very difficult even to
raise low affinity antibodies against human cpn10 by repeated
injections into animals (9). Thus, the different behavior toward
aggregation shown by the cpn10 proteins described in this work
and, in particular, the ability of the M. tuberculosis homologue
to form stable tetrameric species may explain the different
biological activities of cpn10 proteins.
The data on aggregation using the protein’s fragments sug-
gest where, in the sequence, the regions involved in subunit
interactions are approximately located. Thus, the behavior of
peptides 1–58 and 26–99 and the full-length protein clearly
indicates that sequence 1–25 is pivotal to aggregation to tet-
ramers/heptamers. Interestingly, the motif h1PLxD 1 hhhq,
which spans residues 6–15, has been proposed as the cpn10
protein fingerprint (Fig. 1). Here, it is proposed that this se-
quence is one of the regions required for tetramer/heptamer
formation. Another aggregation region may be in the C-termi-
nal half of the protein, although the data are not sufficient for
a more precise and unequivocal location.
Secondary Structure—Central to this discussion are the min-
ima at 198 and 203–204 nm. The first has been traditionally
attributed to the random coil structure. Spectra with similar
characteristics are also of proteins (e.g. soybean trypsin inhib-
itor (34)) whose crystal structure data show to be made of
anti-parallel pleated sheets that either are very much distorted
or contain very short irregular strands (34, 35).
Here, a b-contribution seemed likely due to the structure of
peptide 59–99, which, at low pH, was assigned to a b-sheet,
and the existence in the spectra of all other polypeptides of
minima/shoulders at 215–220 nm. Furthermore, the spectrum
of M. tuberculosis cpn10 in water/MeOH mixtures was that of
proteins with a high b-pleated sheet content. The shoulder
between 225 and 230 nm seen in the spectrum of peptide 1–58
could also be interpreted as deriving from b-sheets since pro-
5 G. Fossati, unpublished observation.
6 F. Marelli, P. Mascagni, and A. R. Coates, unpublished observation.
FIG. 6. CD spectra of E. coli and human (Hu) cpn10 proteins
(0.1 mg/ml) in 0.1 M phosphate buffer, pH 7.4. WL, wavelength.
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teins with this fold and scarce aromatic contribution exhibit a
minimum in this region of the spectrum (31). A contribution of
the random coil type to the structure of the protein and frag-
ments was also probable since the H-a chemical shift of resi-
dues contained in sequence 17–32 of GroES (sequence 19–34 in
M. tuberculosis cpn10) has been shown to be virtually identical
to those reported for random coil peptides (36).
The minimum at 203–204 was more difficult to interpret. Its
assignment to an a-helix seemed unlikely due to the lack of the
intense band at 222 nm. On the other hand, the spectra of both
polyproline II (37) and type I b-turns (Woody’s class C spec-
trum) (38) have minima in this wavelength range.
A more positive assignment derived from the observation
that the main band of monomeric peptides 51–99 and 26–99 is
at 198 nm while the minimum at 203–204 nm and the shoulder
at 215–217 nm characterize the spectra of dimeric peptides
51–99 and 26–99 and tetrameric and heptameric cpn10 pro-
teins. Thus, based on these observations, it was concluded that
the 203–204 nm band correlates with aggregation, whereas the
opposite applies to the minimum at 198 nm. Whether these
changes in quaternary structure are accompanied by changes
in secondary structure (for instance, random coil to polyproline
II-like structure) of parts of the molecule or whether the 203–
204 nm contribution derives directly from the interactions be-
tween subunits cannot be concluded on the basis of these data
only.
FIG. 7. CD spectra of M. tuberculosis (Mt) cpn10 (0.1 mg/ml) in 0.1 M phosphate buffer. A, the protein at different pH values; B, spectra
recorded in the absence and presence of Mg21 (7 mM); C, temperature studies carried out between 0 and 30 °C; D, protein in a 0.1 M
phosphate/MeOH (35:65) mixture. WL, wavelength.
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Changes in the intensities of the 198 and 203–204 nm min-
ima were also observed during the temperature studies of the
full-length protein. In particular, the band at 198 nm became
more intense at 0 °C and vanished almost completely at 30 °C,
where it was replaced by the 204 nm minimum. Since we had
correlated similar changes in secondary structure with changes
in the aggregation state and due to the fact that hydrophobic
interactions are weaker at low temperature (39), we conclude
that the oligomeric structure of the protein is stabilized by
hydrophobic interactions.
Conclusions—The results presented here indicate that for
the M. tuberculosis cpn10 protein, an equilibrium exists in
solution between mainly tetrameric and heptameric forms,
which can be modulated by the protein concentration, the ad-
dition of divalent cations, or the concentration of the phosphate
ion. Monomeric protein was never clearly detected. However,
the need to explain transition from tetramers to heptamers
requires either the presence in solution of small amounts of
monomer or dissociation of tetramers into at least one mono-
meric species and then reassembly into the larger oligomer.
Comparison of the aggregation behavior of the N-terminal and
C-terminal fragments with that of the full-length protein led to
the proposal of sequence 6–15 as one of the protein aggregation
motifs. This conclusion is in agreement with recent data that
indicate that in rat cpn10, the first 1–25 residues are essential
for heptamerization (17).
CD results were consistent with the existence of aggregation
equilibria. The latter could be followed by monitoring the in-
tensity of the minima at 198 and 203–204 nm. The CD data
also permitted us to conclude that the protein adopts a mainly
anti-parallel b-fold consisting of two different regions, each
containing an anti-parallel b-sheet: the first region comprises
residues 1–45, and the second comprises either peptide 55–99
or 59–99, with peptide 46–54 (46–58) forming a large loop
connecting the two sheets. The reasons for these assumptions
were (i) our data that indicate that peptide 59–99 has a spec-
troscopic and aggregation behavior different from that of the
other fragments; (ii) the assignment of peptide 46–58 to a loop
region containing the protein antibody-binding site (5, 27); (iii)
the ability of the protein to adopt a mainly b-fold, as shown by
its CD spectrum in water/MeOHmixtures; and (iv) the recently
published indication that the nearly complete crystal structure
of GroES is made of identical subunits with a mainly b-barrel
fold (40). b-Barrels are generally formed by two b-sheets that
are joined together and packed against each other.
CD data were also used to conclude that the secondary struc-
ture composition of subunits is similar in both stabilized tet-
ramers (i.e. the CD structure at acidic pH values) and heptam-
ers and that contact between subunits is mainly through
hydrophobic forces. Finally, the spectra of E. coli and human
cpn10 molecules were also characterized by minima at 198 and
202–204 nm. Thus, the latter, which was found to correlate
with aggregation, appears to be a general feature of cpn10
molecules.
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